⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Official Title: A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment

Study ID: NCT01646125

Study Description

Brief Summary: The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations. The primary purpose of this study was to compare the efficacy of AUY922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced NSCLC, whose tumors harbored EGFR activating mutations, and had developed resistance to EGFR TKI.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles, California, United States

Maryland Oncology Hematology, P.A. SC, Rockville, Maryland, United States

University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5, Madison, Wisconsin, United States

Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France

Novartis Investigative Site, Creteil, , France

Novartis Investigative Site, Villejuif Cedex, , France

Novartis Investigative Site, Hong Kong, , Hong Kong

Novartis Investigative Site, Monza, MB, Italy

Novartis Investigative Site, Milano, MI, Italy

Novartis Investigative Site, Parma, PR, Italy

Novartis Investigative Site, Orbassano, TO, Italy

Novartis Investigative Site, Koto ku, Tokyo, Japan

Novartis Investigative Site, Seoul, Korea, Korea, Republic of

Novartis Investigative Site, Seoul, Korea, Korea, Republic of

Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of

Novartis Investigative Site, Seoul, , Korea, Republic of

Novartis Investigative Site, Amsterdam, , Netherlands

Novartis Investigative Site, Groningen, , Netherlands

Novartis Investigative Site, Bergen, , Norway

Novartis Investigative Site, Oslo, , Norway

Novartis Investigative Site, Gdansk, , Poland

Novartis Investigative Site, Barcelona, Catalunya, Spain

Novartis Investigative Site, Madrid, , Spain

Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan

Novartis Investigative Site, Taichung, , Taiwan

Novartis Investigative Site, Taipei, , Taiwan

Novartis Investigative Site, Leicester, , United Kingdom

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: